EUROPE CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026
KEY FINDINGS
European countries have shown immense growth in the field of medical sciences and healthcare. The standard quality of life is evidently high in this region and has been altered in the last few years due to the changing needs of society and awareness towards leading a healthy life. The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.96% during the forecast years of 2018-2026.The market value is estimated to reach $xx million by the end of 2026.
MARKET INSIGHTS
The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. Presently, the German CIC drugs market dominates this region. The overall CIC drugs market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is a leading drug in this market.
COMPETITIVE INSIGHTS
Major players in the Europe CIC drug market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.
European countries have shown immense growth in the field of medical sciences and healthcare. The standard quality of life is evidently high in this region and has been altered in the last few years due to the changing needs of society and awareness towards leading a healthy life. The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.96% during the forecast years of 2018-2026.The market value is estimated to reach $xx million by the end of 2026.
MARKET INSIGHTS
The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. Presently, the German CIC drugs market dominates this region. The overall CIC drugs market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is a leading drug in this market.
COMPETITIVE INSIGHTS
Major players in the Europe CIC drug market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING A TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN THE PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. EUROPE CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRY
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF EUROPE
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY CIC DRUGS MANUFACTURERS IN THE MARKET
4.5. MARKET DRIVERS
4.5.1. MODERN DIETARY HABITS TAKING A TOLL ON THE HEALTH
4.5.2. CANCER OR OTHER SYSTEMATIC DISEASE CAN LEAD TO CIC
4.5.3. INCREASING ELDERLY POPULATION
4.5.4. IMPROVED AND EFFICIENT DRUGS IN THE PIPELINE
4.5.5. INCREASING CONSTIPATION PROBLEMS DUE TO SIDE EFFECTS OF PRESCRIBED MEDICINES
4.6. RESTRAINTS
4.6.1. SURGICAL TREATMENTS
4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
4.7.1. HIGH UNMET NEEDS
4.8. CHALLENGES
4.8.1. SIDE EFFECTS OF CIC DRUGS
5. EUROPE CIC DRUGS MARKET, BY DRUG TYPE 2018-2026 ($ MILLION)
5.1. OVERVIEW
5.1.1. LUBIPROSTONE
5.1.2. LINACLOTIDE
5.1.3. OTHERS
5.2. PIPELINE DRUG ANALYSIS: PHASE 3: PLECANATIDE (YEAR OF LAUNCH 2022, $ MILLION)
5.3. PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH 2022, $ MILLION)
6. EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
6.1. PRESCRIBED DRUGS
6.2. OVER THE COUNTER DRUGS
7. KEY ANALYTICS
7.1. PORTER’S FIVE FORCE ANALYSIS
7.1.1. INTENSITY OF COMPETITIVE RIVALRY
7.1.2. BARGAINING POWER OF SUPPLIERS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. THREAT OF SUBSTITUTE PRODUCTS
7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX
8. EUROPE CIC DRUGS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
8.1. UK
8.2. GERMANY
8.3. REST OF EUROPE
9. COMPANY PROFILES
9.1. ALLERGENS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC MOVES
9.1.4. SCOT ANALYSIS
9.2. CHUGAI PHARMACEUTICAL
9.2.1. OVERVIEW
9.2.2. PRODUCTS PORTFOLIO
9.2.3. STRATEGIC MOVES
9.2.4. SCOT ANALYSIS
9.3. FERRING INTERNATIONAL CENTER S.A.
9.3.1. OVERVIEW
9.3.2. PRODUCTS PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. SYNERGY PHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. PRODUCTS PORTFOLIO
9.4.3. SCOT ANALYSIS
9.5. PFIZER
9.5.1. OVERVIEW
9.5.2. PFIZER PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. GLAXOSMITHKLINE
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. ROCHE HOLDING AG
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC MOVES
9.7.4. SCOT ANALYSIS
9.8. SANOFI
9.8.1. OVERVIEW
9.8.2. PRODUCTS PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. BAYER AG
9.9.1. OVERVIEW
9.9.2. PRODUCTS PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. MERCK SHARP & DOHME
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. ELI LILLY AND COMPANY
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.12. SALIX PHARMACEUTICALS LTD
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.13. SUCAMPO PHARMACEUTICALS INC
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.14. IRONWOOD PHARMACEUTICALS INC
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.15. VALEANT PHARMACEUTICALS INTERNATIONAL
9.15.1. OVERVIEW
9.16. DAIICHI SANKYO CO LTD
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.17. COSMO PHARMACEUTICALS SA
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.18. PROGENICS PHARMACEUTICALS INC
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.19. THERAVANCE BIOPHARMA INC
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. SCOT ANALYSIS
LIST OF TABLES
TABLE 1 EUROPE CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 EUROPE CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 EUROPE CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 14 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 15 UK CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 16 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 17 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 1 EUROPE CIC DRUG MARKET BY COUNTRIES 2018-2026 ($ MILLION)
TABLE 2 PROMINENT DRUGS AND THEIR RESPECTIVE COMPANIES IN THERAPEUTICS FOR CHRONIC CONSTIPATION
TABLE 3 CONSTIPATION IN PARKINSON’S DISEASE
TABLE 4 COMMON MEDICINES CAUSING CONSTIPATION
TABLE 5 EUROPE CIC DRUGS MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
TABLE 6 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 7 PRODUCT PROFILE (LINACLOTIDE)
TABLE 8 PRODUCT PROFILE (BISACODYL)
TABLE 9 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 10 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)
TABLE 11 EUROPE CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 12 LINZESS PRECAUTIONS AND SIDE EFFECTS
TABLE 13 EUROPE CIC DRUGS MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 14 UK CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 15 UK CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
TABLE 16 GERMANY CIC DRUGS MARKET BY PRESCRIPTION TYPE 2018-2026 ($ MILLION)
TABLE 17 GERMANY CIC DRUGS MARKET BY MAJOR DRUGS 2018-2026 ($ MILLION)
LIST OF FIGURES
FIGURE 1 EUROPE CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 2 EUROPE CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
FIGURE 3 EUROPE CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 11 EUROPE LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 12 EUROPE LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 13 EUROPE OTHER DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 14 EUROPE PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 15 EUROPE OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 16 EUROPE CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 17 UK CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 18 GERMANY CIC DRUG MARKET, 2018-2026 $ MILLION)
FIGURE 19 REST OF EUROPE CIC DRUG MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ALLERGENS
2. CHUGAI PHARMACEUTICAL
3. FERRING INTERNATIONAL CENTER S.A.
4. SYNERGY PHARMACEUTICALS
5. PFIZER
6. GLAXOSMITHKLINE
7. ROCHE HOLDING AG
8. SANOFI
9. BAYER AG
10. MERCK SHARP & DOHME
11. ELI LILLY AND COMPANY
12. SALIX PHARMACEUTICALS LTD
13. SUCAMPO PHARMACEUTICALS INC
14. IRONWOOD PHARMACEUTICALS INC
15. VALEANT PHARMACEUTICALS INTERNATIONAL
16. DAIICHI SANKYO CO LTD
17. COSMO PHARMACEUTICALS SA
18. PROGENICS PHARMACEUTICALS INC
19. THERAVANCE BIOPHARMA INC
FIGURE 1 EUROPE CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 2 EUROPE CIC DRUG MARKET BY DRUG TYPE 2018-2026 ($ MILLION)
FIGURE 3 EUROPE CIC DRUG MARKET BY PRESCRIPTION TYPE IN 2017 ($ MILLION)
FIGURE 4 CAUSES OF CONSTIPATION
FIGURE 5 PROPORTION OF POPULATION AGED 60 OR ABOVE IN 2014
FIGURE 6 MAJOR CAUSES OF CONSTIPATION IN ELDERLY PEOPLE
FIGURE 7 EFFECTIVE DRUGS TO CREATE HUGE MARKET BENEFITS
FIGURE 8 SURGICAL OPTIONS AVAILABLE FOR CONSTIPATION
FIGURE 9 NEED OF SURGERY PROCESS
FIGURE 10 COMMON CONSTIPATION DRUGS AND SIDE EFFECTS CAUSED DUE TO THEM
FIGURE 11 EUROPE LUBIPROSTONE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 12 EUROPE LINACLOTIDE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 13 EUROPE OTHER DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 14 EUROPE PRESCRIBED CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 15 EUROPE OVER THE COUNTER CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 16 EUROPE CIC DRUGS MARKET 2018-2026 ($ MILLION)
FIGURE 17 UK CIC DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 18 GERMANY CIC DRUG MARKET, 2018-2026 $ MILLION)
FIGURE 19 REST OF EUROPE CIC DRUG MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ALLERGENS
2. CHUGAI PHARMACEUTICAL
3. FERRING INTERNATIONAL CENTER S.A.
4. SYNERGY PHARMACEUTICALS
5. PFIZER
6. GLAXOSMITHKLINE
7. ROCHE HOLDING AG
8. SANOFI
9. BAYER AG
10. MERCK SHARP & DOHME
11. ELI LILLY AND COMPANY
12. SALIX PHARMACEUTICALS LTD
13. SUCAMPO PHARMACEUTICALS INC
14. IRONWOOD PHARMACEUTICALS INC
15. VALEANT PHARMACEUTICALS INTERNATIONAL
16. DAIICHI SANKYO CO LTD
17. COSMO PHARMACEUTICALS SA
18. PROGENICS PHARMACEUTICALS INC
19. THERAVANCE BIOPHARMA INC
